RESUMEN
Objective To explore the efficacy and safety of single or combine using radionuclide 89SrCl2/Yunke in cancer patients with bone metastasis. Methods Four hundred and one cancer patients with bone metas-tasis during 2012 Jan to 2016 Jan in Affiliated Tumor Hospital of Guangxi Medical University were included by a prospective study. According to different therapy ,these patients were randomly divided into three groups:radionu-clide 89SrCl2 group(n=111),Yunke group(n=130)and combined therapy group(n=160). The effect of pain relief and adverse reaction among three groups were compared after therapy. Results Compared with single using radionuclide 89SrCl2 or Yunke ,the cancer pain and bone metastasis in combined-using group were significantly re-lieved with effective rate of 91.25%and 98.75%respectively;the incidence of'pain shine'(11.7%),leucopenia (10.8%)and thrombocytopenia(6.3%)in combined-using group were both lower than single-using group. The ef-fective rate of cancer pain and bone metastasis relief ,and incidence of adverse reaction among single using radionu-clide 89SrCl2 or Yunke were similar. Conclusion Combined-using radionuclide 89SrCl2 and Yunke would effectively and safely relieve cancer with bone metastasis.
RESUMEN
Objective To explore the efficacy and safety of single or combine using radionuclide 89SrCl2/Yunke in cancer patients with bone metastasis. Methods Four hundred and one cancer patients with bone metas-tasis during 2012 Jan to 2016 Jan in Affiliated Tumor Hospital of Guangxi Medical University were included by a prospective study. According to different therapy ,these patients were randomly divided into three groups:radionu-clide 89SrCl2 group(n=111),Yunke group(n=130)and combined therapy group(n=160). The effect of pain relief and adverse reaction among three groups were compared after therapy. Results Compared with single using radionuclide 89SrCl2 or Yunke ,the cancer pain and bone metastasis in combined-using group were significantly re-lieved with effective rate of 91.25%and 98.75%respectively;the incidence of'pain shine'(11.7%),leucopenia (10.8%)and thrombocytopenia(6.3%)in combined-using group were both lower than single-using group. The ef-fective rate of cancer pain and bone metastasis relief ,and incidence of adverse reaction among single using radionu-clide 89SrCl2 or Yunke were similar. Conclusion Combined-using radionuclide 89SrCl2 and Yunke would effectively and safely relieve cancer with bone metastasis.
RESUMEN
Objective To evaluate the effect of YunKe on bone metabolism of patients with rheumatoid arthritis (RA). Methods A total of 108 RA patients were divided into YunKe group (n = 72), non-YunKe group (n = 36), and 54 controls. The bone mineral densities (BMDs) of the wrists, hips and lumbar spines were measured by dual-energy X-ray absorptiometry. Moreover , the expression of cross-linked N-telopeptides of type I collagen (NTX) in the serum was detected for statistically analyzing the difference between YunKe group and non-YunKe group. Results In RA group, the BMDs of wrist, hip and lumbar spine declined compared with that of control group (P < 0.001, respectively). In YunKe group, the BMDs of wrist, hip and lumbar spine after 6 months all were improved with statistically significance (P < 0.01, respectively); The differences also were statistically significant when compared with those in non-YunKe group (P < 0.01, respectively). In YunKe group, NTX level in the serum declined after 3 months of the treatment. The difference was statistically significant when compared with that in non-YunKe group (P < 0.001), but the difference disappeared 6 months later. Conclusions The BMD of wrist joints is low and declines in RA patients significantly. The treatment withYunKe improves the BMDs of the wrist , hip and lumbar spine and decreases the serum NTX. This study proposed that YunKe could inhibit the chronic loss of bone mass induced by RA.